Skip to Content

Interferon alfa-2a Pregnancy and Breastfeeding Warnings

Interferon alfa-2a is also known as: Roferon-A

Interferon alfa-2a Pregnancy Warnings

Interferon alfa-2a has been assigned to a pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. Doses of 20 to 500 times the human dose demonstrated a statistically significant increase in abortifacient activity in rhesus monkeys. There are no controlled data in human pregnancy. Decreases in serum estradiol and progesterone concentrations have been reported in women treated with human leukocyte interferon. Fertile women should not receive interferon alfa-2a unless they are using effective contraception.

See references

Interferon alfa-2a Breastfeeding Warnings

There are no data on the excretion of interferon alfa-2a into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from interferon alfa-2a, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Roferon-A Injection (interferon alfa-2a)." Roche Laboratories, Nutley, NJ.

References for breastfeeding information

  1. "Product Information. Roferon-A Injection (interferon alfa-2a)." Roche Laboratories, Nutley, NJ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.